Afya Limited (NASDAQ:AFYA) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Afya Limited (NASDAQ:AFYA) has received a consensus rating of "Hold" from six analysts, with one sell, four hold, and one buy recommendation.
• The average price target among analysts is set at $17.50, reflecting varied opinions on the stock's potential.
• Afya operates as a medical education group in Brazil, offering a range of services including medical schools and continuing education programs.

Shares of Afya Limited (NASDAQ:AFYA - Get Free Report) have been assigned an average rating of "Hold" from the six analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $17.50.

A number of research firms have recently commented on AFYA. UBS Group reissued a "neutral" rating and set a $19.50 target price (up from $17.50) on shares of Afya in a research report on Thursday, June 12th. Zacks Research raised shares of Afya to a "hold" rating in a research report on Friday, August 8th. Citigroup raised shares of Afya from a "sell" rating to a "neutral" rating and reduced their target price for the stock from $16.00 to $14.00 in a research report on Tuesday, July 29th. Wall Street Zen upgraded shares of Afya from a "hold" rating to a "buy" rating in a research note on Friday. Finally, Morgan Stanley set a $17.50 price target on shares of Afya and gave the stock an "overweight" rating in a research note on Wednesday, August 6th.

Institutional Trading of Afya

A number of hedge funds and other institutional investors have recently made changes to their positions in AFYA. JPMorgan Chase & Co. increased its stake in shares of Afya by 2,115.9% in the fourth quarter. JPMorgan Chase & Co. now owns 6,670 shares of the company's stock worth $106,000 after buying an additional 6,369 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Afya by 1,099.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,031 shares of the company's stock worth $64,000 after buying an additional 3,695 shares during the last quarter. Aquatic Capital Management LLC increased its stake in shares of Afya by 47.6% in the fourth quarter. Aquatic Capital Management LLC now owns 9,300 shares of the company's stock worth $148,000 after buying an additional 3,000 shares during the last quarter. Northern Trust Corp increased its stake in shares of Afya by 109.7% in the fourth quarter. Northern Trust Corp now owns 40,054 shares of the company's stock worth $636,000 after buying an additional 20,957 shares during the last quarter. Finally, PDT Partners LLC increased its stake in Afya by 21.2% during the fourth quarter. PDT Partners LLC now owns 34,132 shares of the company's stock valued at $542,000 after purchasing an additional 5,964 shares during the last quarter. Institutional investors own 88.02% of the company's stock.

Afya Stock Down 0.2%

Shares of NASDAQ AFYA traded down $0.03 during trading on Thursday, reaching $15.04. 128,846 shares of the stock were exchanged, compared to its average volume of 108,404. The business's 50-day moving average price is $15.69 and its 200 day moving average price is $17.16. Afya has a twelve month low of $13.47 and a twelve month high of $19.90. The company has a quick ratio of 0.94, a current ratio of 0.94 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of 11.39, a price-to-earnings-growth ratio of 0.53 and a beta of 0.53.

Afya Company Profile

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.